What is the ROE (Return on Equity) of Pharma Mar this year?
The ROE of Pharma Mar this year is 0.01 undefined.
Pharma Mar ROE 2024
Pharma Mar ROE
0.01
Ticker
PHM.MC
ISIN
ES0169501022
WKN
A2P9YT
In 2024, Pharma Mar's return on equity (ROE) was 0.01, a -97.34% increase from the 0.22 ROE in the previous year.
Pharma Mar Aktienanalyse
What does Pharma Mar do?
Pharma Mar SA is a biopharmaceutical company based in Madrid, Spain, focused on developing and marketing innovative cancer treatments. The company originated from Zeltia SA, a business group founded in 1963 that was previously active in various sectors including shipbuilding and fishing. In 1986, Zeltia SA expanded into the pharmaceutical industry and established Pharma Mar SA to concentrate on researching and developing cancer therapies. Over the years, Pharma Mar SA expanded its portfolio through acquisitions and partnerships, such as the acquisition of the biotech company Sylentis in 2006 and a strategic collaboration with Janssen Pharmaceutica in 2014. Today, Pharma Mar SA's business model consists of researching, developing, and marketing cancer treatments based on marine organisms. The company has built an extensive library of marine organisms from which it identifies and develops potential compounds for cancer therapy. Pharma Mar SA is divided into three main business areas: oncology, ophthalmology, and diagnostics. The oncology division focuses on developing and marketing drugs for the treatment of various types of cancer, such as lung cancer, breast cancer, ovarian cancer, and small cell lung cancer. One of Pharma Mar SA's key products in the oncology field is Yondelis, a medication for the treatment of soft tissue sarcomas and ovarian cancer. Yondelis was developed by Pharma Mar SA in collaboration with Janssen Pharmaceutica and is the first medication approved by the European Medicines Agency for the treatment of soft tissue sarcomas. The ophthalmology division focuses on researching and developing drugs for the treatment of eye diseases such as dry eye and retinitis pigmentosa. Pharma Mar SA has a promising pipeline of products in early development, including p118, a compound for the treatment of dry eye that is currently being tested in clinical trials. The diagnostics division focuses on the development of innovative diagnostics for the early detection of cancer and other diseases. Pharma Mar SA has a range of products in development, including a blood test for the detection of lung cancer based on the identification of tumor markers. Overall, Pharma Mar SA has an impressive track record in the development and marketing of cancer treatments from marine organisms. The company has launched several products that contribute to improving the lives of cancer patients and has a promising pipeline of products in development that have the potential to revolutionize the treatment of cancer and other diseases. Pharma Mar ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Pharma Mar's Return on Equity (ROE)
Pharma Mar's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Pharma Mar's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Pharma Mar's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Pharma Mar’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Pharma Mar stock
How has the Return on Equity (ROE) of Pharma Mar developed compared to the previous year?
The ROE of Pharma Mar has increased by -97.34% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Pharma Mar?
A high ROE indicates that Pharma Mar generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Pharma Mar?
A low ROE can indicate that Pharma Mar is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Pharma Mar affect the company?
A change in ROE (Return on Equity) of Pharma Mar can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Pharma Mar?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Pharma Mar?
Some factors that can influence Pharma Mar's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Pharma Mar pay?
Over the past 12 months, Pharma Mar paid a dividend of 0.65 EUR . This corresponds to a dividend yield of about 1.64 %. For the coming 12 months, Pharma Mar is expected to pay a dividend of 0.77 EUR.
What is the dividend yield of Pharma Mar?
The current dividend yield of Pharma Mar is 1.64 %.
When does Pharma Mar pay dividends?
Pharma Mar pays a quarterly dividend. This is distributed in the months of May, August, July, July.
How secure is the dividend of Pharma Mar?
Pharma Mar paid dividends every year for the past 9 years.
What is the dividend of Pharma Mar?
For the upcoming 12 months, dividends amounting to 0.77 EUR are expected. This corresponds to a dividend yield of 1.94 %.
In which sector is Pharma Mar located?
Pharma Mar is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharma Mar kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharma Mar from 6/14/2024 amounting to 0.65 EUR, you needed to have the stock in your portfolio before the ex-date on 6/12/2024.
When did Pharma Mar pay the last dividend?
The last dividend was paid out on 6/14/2024.
What was the dividend of Pharma Mar in the year 2023?
In the year 2023, Pharma Mar distributed 0.65 EUR as dividends.
In which currency does Pharma Mar pay out the dividend?
The dividends of Pharma Mar are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharma Mar
Our stock analysis for Pharma Mar Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharma Mar Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
